Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

医学 肺病 随机对照试验 慢性阻塞性肺病 荟萃分析 重症监护医学 系统回顾 内科学 梅德林 政治学 法学
作者
Tyler Pitre,Dániel Lupas,Jasmine Cassy Mah,Matthew B. Stanbrook,Alina J. Blazer,Dena Zeraatkar,Terence N. Ho
出处
期刊:COPD: Journal of Chronic Obstructive Pulmonary Disease [Informa]
卷期号:22 (1): 2449889-2449889 被引量:32
标识
DOI:10.1080/15412555.2025.2449889
摘要

BACKGROUND: Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking. METHODS: We conducted a systematic review of MEDLINE, EMBASE, and Cochrane CENTRAL from inception to July 17, 2024, to identify randomized trials of biologic medications in patients with COPD. We performed a random effects frequentist network meta-analysis and present the results using relative risk (RR) and 95% confidence intervals (CI). We used the GRADE framework to rate the certainty of the evidence. Outcomes of interest included exacerbations, change in FEV1, change in quality of life, and serious adverse events. RESULTS: Dupilumab reduced exacerbations as compared to placebo (RR 0.68 [95% CI 0.59 to 0.79]) (high certainty). Benralizumab (RR 0.89 [95% CI 0.78 to 1]), itepekimab (RR 0.81 [95% CI 0.61 to 1.07]) and tezepelumab (RR 0.83 [95% CI 0.61 to 1.12]) may reduce exacerbations as compared to placebo (all low certainty). Dupilumab probably reduced exacerbations more than mepolizumab (RR 0.74 [95% CI 0.62 to 0.89]) (moderate certainty). Dupilumab may reduce exacerbations more than tezepelumab (RR 0.82 [95% CI 1.14]) (low certainty). For all patients, no treatment improved FEV1 above the pre-specified minimal clinically important difference (MCID) of 0.1 L. Dupilumab probably has no meaningful effect on FEV1 compared to placebo (MD 0.07 [95% CI 0.02 to 0.13]) (moderate certainty). However, in the subgroup of patients with blood eosinophils ≥300/mcL, both tezepelumab (MD 0.15 [95% CI 0.05 to 0.26]) and dupilumab (MD 0.13 [95% CI 0.06 to 0.19]) probably improved FEV1 above the MCID. CONCLUSION: Dupilumab is effective at improving patient-relevant outcomes in COPD with higher eosinophil levels. Other biological therapies, including tezepelumab, have no important effect on patient-relevant outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
任雨净完成签到,获得积分10
刚刚
CodeCraft的应助被蓝天采纳,获得10
刚刚
学霸业的应助被蓝天采纳,获得10
1秒前
皮皮发布了新的文献求助10
2秒前
挚友发布了新的文献求助30
2秒前
袁帅完成签到 ,获得积分10
2秒前
2秒前
小呆瓜完成签到,获得积分20
3秒前
Danger完成签到 ,获得积分10
4秒前
LUXURY发布了新的文献求助10
4秒前
田园发布了新的文献求助10
5秒前
Hello的应助被小九九采纳,获得30
5秒前
深情安青的应助被科研通管家采纳,获得10
5秒前
搜集达人的应助被科研通管家采纳,获得10
6秒前
6秒前
脑洞疼的应助被科研通管家采纳,获得10
6秒前
无极微光的应助被科研通管家采纳,获得20
6秒前
6秒前
Akim的应助被科研通管家采纳,获得10
6秒前
Hello的应助被科研通管家采纳,获得10
6秒前
所所的应助被科研通管家采纳,获得10
6秒前
Akim的应助被Bobo采纳,获得10
6秒前
大个的应助被科研通管家采纳,获得10
7秒前
SciGPT的应助被科研通管家采纳,获得10
7秒前
英俊的铭的应助被Bobo采纳,获得10
7秒前
完美世界的应助被科研通管家采纳,获得30
7秒前
李健的应助被Bobo采纳,获得10
7秒前
7秒前
7秒前
无花果的应助被科研通管家采纳,获得10
7秒前
在水一方的应助被科研通管家采纳,获得10
7秒前
隐形曼青的应助被Twinkle采纳,获得30
7秒前
上岸的风的应助被科研通管家采纳,获得10
7秒前
荀汐发布了新的文献求助10
8秒前
爆米花的应助被科研通管家采纳,获得10
8秒前
852的应助被科研通管家采纳,获得10
8秒前
英俊的铭的应助被科研通管家采纳,获得10
8秒前
领导范儿的应助被科研通管家采纳,获得10
8秒前
无极微光的应助被科研通管家采纳,获得20
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189431
求助须知:如何正确求助?哪些是违规求助? 9576755
关于积分的说明 21849578
捐赠科研通 7787361
什么是DOI,文献DOI怎么找? 3435577
关于科研通互助平台的介绍 2559772
邀请新用户注册赠送积分活动 2482529